The U.S. Supreme Court is considering whether an Amgen patent is invalid for not meeting the enablement requirements of Section 112(a). It claims antibodies by functional antigen binding and does not disclose the full range of antibody sequences. Three Procopio IP Partners--experts in patent prosecution and patent litigation--discuss the background of the case, in particular how the High Court’s decision may impact the ability to obtain certain life science, chemical and pharma patents and how it may provide additional ammunition to See more +

The U.S. Supreme Court is considering whether an Amgen patent is invalid for not meeting the enablement requirements of Section 112(a). It claims antibodies by functional antigen binding and does not disclose the full range of antibody sequences. Three Procopio IP Partners--experts in patent prosecution and patent litigation--discuss the background of the case, in particular how the High Court’s decision may impact the ability to obtain certain life science, chemical and pharma patents and how it may provide additional ammunition to attack such patents in patent litigation.

The discussion includes IP Partner Jeff Morton, PhD, based in San Diego and leader of Procopio's Life Sciences group; IP Litigation Partner Robert Sloss, based in Palo Alto; and Jeremy Edwards, based in Washington, D.C. See less -